Weight gain in treatment-naive HIV-1 infected patients starting abacavir/lamivudine/dolutegravir or tenofovir alafenamide/emtricitabine/bictegravir

Long-term weight gain after initiating combination antiretroviral therapy in treatment-naïve Asian people living with human immunodeficiency virus

(2021) Naokatsu Ando et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

An assessment of weight change associated with the initiation of a protease or integrase strand transfer inhibitor in patients with Human Immunodeficiency Virus

(2020) Wing Chow et al.   CURRENT MEDICAL RESEARCH AND OPINION

Weight gain among treatment‐naïve persons with HIV starting integrase inhibitors compared to non‐nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada

(2020) Kassem Bourgi et al.   Journal of the International AIDS Society

Factors associated with weight gain in people treated with dolutegravir

(2020) Lucia Taramasso et al.   Open Forum Infectious Diseases

Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials

(2020) Chloe Orkin et al.   Lancet HIV

Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial

(2020) Willem D F Venter et al.   Lancet HIV

Brief Report: Weight Gain Following ART Initiation in ART-Naïve People Living With HIV in the Current Treatment Era

(2020) Stephanie A. Ruderman et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Greater Weight Gain in Treatment Naïve Persons Starting Dolutegravir-Based Antiretroviral Therapy

(2019) Kassem Bourgi et al.   CLINICAL INFECTIOUS DISEASES